Key facts
- This page summarizes Sire Group Ltd.'s Form 3 filing for TITAN PHARMACEUTICALS INC (TTNP).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Oct 2023, 16:40.
Sire Group Ltd. - 13 Sep 2023 Form 3 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TTNP
- Reported as of
- 13 Sep 2023
- Net transaction value
- $0
- Reporting owner signature
- THE SIRE GROUP LTD, By: /s/ Seow Gim Shen, Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Sire Group Ltd. filed Form 3 for TITAN PHARMACEUTICALS INC (TTNP) on 04 Oct 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TTNP
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,836,266
- Date
- 13 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TTNP
holding
Derivative
Series AA Convertible Preferred Stock ("Preferred Stock")
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 13 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,836,266
- Exercise price
- $0.4660
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The total number of shares into which the Preferred Stock ultimately is convertible is as set forth in the table, but the Preferred Stock contains restrictions limiting the number of converted shares that the reporting persons may have at any one time, without Issuer stockholder approval, to 3,001,757 shares.
Footnote F2
Seow Gim Shen owns the shares beneficial ownership is indirect, by virtue of his sole ownership of The Sire Group Ltd., which owns the shares directly.
Footnote F3
Not Applicable